To identify additional prognostic biomarkers in patients receiving ICI-based immunotherapy, we evaluated the publicly available genomic data from the MSKCC pan-cancer cohort of 1661 patients, restricting analysis to patients receiving PD-1, PD-L1, and/or CTLA-4 inhibitors20. This evidence concerns the gene CTLA4 and cancer.